Radiopharmacokinetic data for Tc-99m-ABP - A new radiopharmaceutical for bone scanning: Comparison with Tc-99m-MDP

被引：12

作者：

deMurphy, CA

MelendezAlafort, L

MontoyaMolina, CE

SepulvedaMendez, J

机构：

[1] Inst. Nac. de Nutr. Salvador Zubiran, México City

[2] Depto. Med. Nucl. y Clin. Tiroides, Inst. Nac. de Nutr. Salvador Zubiran, Delegación Tlalpan D.F. 1400

来源：

NUCLEAR MEDICINE AND BIOLOGY | 1997年 / 24卷 / 01期

关键词：

pharmacokinetics-radioactive-alendronate; Technetium-99mTc-alendronate-pharmacokinetics; diphosphonate-99mTc-ABP-pharmacokinetics; bone scan-99mTc-alendronate;

D O I：

10.1016/S0969-8051(96)00151-5

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Technetium-99m-labeled alendronate is a new radiopharmaceutical for bone scanning developed under strict quality control at the INNSZ, The purpose of this work was to compare the radiopharmacokinetic data and the dosimetry of Tc-99m-ABP and Tc-99m-MDP in 10 volunteers, after it was tested in laboratory animals. Tc-99m-ABP has shorter mean residence time (MRT) and t(1/2) beta; is less protein bound; has a higher renal clearance; smaller Vdss, and similar bone uptake at 1 and 2 h. Tc-99m-ABP gives less radiation exposure to the patient with a 740 MBq dose, and the quality of the bone scan is excellent. Tc-99m-ABP is a better radiopharmaceutical than Tc-99m-MnP for bone scanning. Copyright (C) 1997 Elsevier Science Inc.

引用

页码：27 / 33

页数：7

共 31 条

[1]

ADANI S, 1993, OSTEOPOROSIS INT, V3, P21

[2]

ANDERSON DC, 1993, OSTEOPOROSIS INT, V3, P41

[3]

Castronovo EP, 1972, J NUCL MED, V13, P823

[4]

CLANTON JA, 1987, ESSENTIALS NUCL MED

[5]

COLLIER BD, 1995, PRINCIPLES PRACTICE, P339

[6]

DEMURPHY CA, IN PRESS ARCH MED RE

[7]

DEMURPHY CA, 1992, MANUAL RADIOFARMACOC, P1

[8]

DIPIRO JT, 1988, CONCEPTS CLINICAL PH

[9]

FLEISCH H, 1993, OSTEOPOROSIS INT, V3, P3

[10]

GERTZ BJ, 1993, OSTEOPOROS INT S3, V3, P13

← 1 2 3 4 →